SCHEMBL645530

SCHEMBL645530

Cn1nnc(-c2ccc(CN3CCC(O)(C(O)(c4ccc(OC(F)(F)F)cc4)c4ccc(OC(F)(F)F)cc4)CC3)cc2)n1

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.48
LMNA P02545 1/20 0.44
TSHR P16473 1/20 0.43
MMP2 P08253 2/20 0.43
MMP3 P08254 2/20 0.43
MMP9 P14780 2/20 0.43
MMP8 P22894 2/20 0.43
MMP13 P45452 2/20 0.43
MMP7 P09237 1/20 0.43
CCR6 P51684 7/20 0.41
KCNH2 Q12809 5/20 0.41
STAT3 P40763 1/20 0.39
LSS P48449 1/20 0.39
CHRM2 P08172 1/20 0.38
CHRM1 P11229 1/20 0.38
HDAC6 Q9UBN7 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7466544 0.83 ALDH1A1 (0.49) ALDH1A1TSHRCCR6KCNH2STAT3
SCHEMBL13846113 0.75 NPC1 (0.52) ALDH1A1KCNH2
SCHEMBL3544658 0.72 ALDH1A1 (0.40) ALDH1A1TSHRSTAT3CHRM2CHRM1
SCHEMBL645285 0.72 KMT2A (0.45) ALDH1A1LMNATSHR
SCHEMBL7464967 0.71 DNMT1 (0.54) ALDH1A1LMNAKCNH2HDAC6
SCHEMBL646390 0.70 KMT2A (0.45) ALDH1A1LMNATSHR
SCHEMBL3543064 0.69 ALDH1A1 (0.41) ALDH1A1TSHRMMP2MMP3MMP9
SCHEMBL30326961 0.69 CCR6 (0.64) CCR6KCNH2
SCHEMBL30327238 0.69 CCR6 (0.64) CCR6KCNH2
SCHEMBL30326859 0.69 CCR6 (0.64) CCR6KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119563-B2 N-substituted azacycles FMC CORPORATION (US) 2012-02-21 US disclosed
US-8119563-B2 N-substituted azacycles FMC CORPORATION (US) 2012-02-21 US disclosed
US-8119563-B2 N-substituted azacycles FMC CORPORATION (US) 2012-02-21 US disclosed
US-20090215821-A1 N-Substituted Azacycles FMC CORPORATION 2009-08-27 US disclosed
US-20090215821-A1 N-Substituted Azacycles FMC CORPORATION 2009-08-27 US disclosed
US-20090215821-A1 N-Substituted Azacycles FMC CORPORATION 2009-08-27 US disclosed
EP-1673083-A4 N-SUBSTITUTED AZACYCLES BAYER CROPSCIENCE AG (DE) 2008-12-17 EP disclosed
EP-1673083-A2 N-SUBSTITUTED AZACYCLES FMC CORPORATION (US) 2006-06-28 EP disclosed
WO-2005036961-A2 N-SUBSTITUTED AZACYCLES FMC CORPORATION (US) 2005-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215821-A1 N-Substituted Azacycles DDT, UQCRB, DNMT1 ALDH1A1 2697/4885LMNA 2453/4885TSHR 1037/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.